Skip to main content
Premium Trial:

Request an Annual Quote

BioSystem Development Closes $1M Financing Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioSystem Development has closed a financing round raising just over $1 million, the firm said after the close of the market Wednesday.

The privately-held firm said that it will use the funds to scale up its manufacturing capabilities, increase the speed to market of its new products, and support expansion of its product pipeline. The Madison, Wis.-based company makes the AssayMap platform, which enables high-throughput solutions for bioprocess development, biomarkers, and life sciences research.

BioSystem Development said that a total of $750,000 of new equity was raised in the round from angel investors. An additional $300,000 came in the form of a loan from the Madison Development Corporate Venture Debt Fund.

The firm inked a deal last year with Agilent Technologies to integrate Agilent's Bravo automated liquid handling platform with BioSystem Development's AssayMap technology. Under that alliance, Agilent's Bravo with 96AM head was combined with AssayMap cartridges packed with chromatographic resin or immobilized enzyme to create an open-platform instrument for protein sample preparation and processing.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.